Sanofi: FDA Approves Use of 0.5 mL Dose of Influenza Vaccine in Children as Young as 6 Months of Age

Originally Published by Sanofi.

The U.S. Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone Quadrivalent (influenza vaccine) to include children age 6 through 35 months. Sanofi Pasteur, the vaccine division of Sanofi, will have the 0.5 mL dose, in addition to the 0.25 mL dose, available for the upcoming 2019-20 season for this expanded age range.


“Offering pediatricians the convenience of the same 0.5 mL dose option for children, may help streamline immunization efforts,” said Dr. David P. Greenberg, Regional Medical Head North America, Sanofi Pasteur. “The potentially life-threatening effects of influenza in children reported during the 2017-18 season, especially among those who were not vaccinated, is sobering. We commit ourselves every day to bring solutions to help meet ongoing public health needs related to influenza, especially among vulnerable groups such as young children.”

Today’s approval is supported by clinical data from a Phase IV safety and immunogenicity study conducted in nearly 2,000 children, which demonstrated that one or two doses of 0.5 mL of vaccine in children 6 through 35 months of age had a safety profile that was comparable to one or two doses of 0.25 mL of vaccine with no new safety concerns observed, and induced a robust immune response. Detailed results were presented at the Pediatric Academic Societies meeting in April 2018, as well as at the Advisory Committee on Immunization Practices meeting and the American Academy of Family Physicians Family Medicine Experience conference in October 2018.

Sanofi Pasteur’s flu vaccine portfolio includes options to help protect all eligible patients from influenza. In addition to Fluzone Quadrivalent vaccine, the product portfolio includes Flublok Quadrivalent (influenza vaccine) and Fluzone High-Dose (influenza vaccine), the only two flu vaccines proven to help prevent more cases of flu in older adults, compared to their standard-dose flu vaccine comparators in randomized controlled trials. In these same trials, the most common local and systemic adverse reactions to Flublok Quadrivalent and Fluzone High-Dose vaccines include pain at the injection site, headache and myalgia.

Health care providers can place 2019-20 reservations for all Sanofi Pasteur vaccines, including the 0.5 mL presentations of Fluzone Quadrivalent vaccine for use in all appropriate pediatric patients via www.VaccineShoppe.com. The 0.25 mL dose of Fluzone Quadrivalent vaccine will remain available for 2019-20 reservations.

Latest News

What To Know About Hispanic Heritage Month

Every year, the month between Sept. 15 and Oct. 15 offers schools, workplaces and cultural institutions the chance to focus on Hispanic people and their culture during Hispanic Heritage Month. The annual event celebrates U.S. citizens from Spain, Mexico, the Caribbean, and Central and South America with a focus on…

5 Biggest News Stories of the Week: September 23

As the saying goes, the news never stops — but there’s a lot of it out there, and all of it doesn’t always pertain to our readers. In this weekly news roundup, we’ll cover the top news stories that matter most to our diversity focused audience. 1. Women of Color…

3 Court Cases That Have Taken Religious Freedoms Too Far

As upheld by the First Amendment, anyone and everyone has the right to practice their religion of choice or not practice one at all. While people have the right to go to court when they feel their religious freedoms are infringed upon, those cases have sometimes yielded results that beg…

Dow Receives Four Sustainability Awards From the Business Intelligence Group

Originally published at corporate.dow.com. Dow ranked No. 15 on The DiversityInc Top 50 Companies for Diversity list in 2022.   Dow’s global sustainability efforts were recognized with four prestigious 2022 Business Intelligence Group (BIG) Sustainability Awards. The Sustainability Awards honor those people, teams and organizations who have made sustainability an…